In this edition of The Motley Fool's health care show, Market Checkup, analysts David Williamson and Max Macaluso take a close look at two of the most prominent potential turnaround stories in the pharmaceutical space: generic drugmaker Teva and struggling giant AstraZeneca.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The Motley Fool's health care show, Market Checkup, for Sept. 9, 2013.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Eli Lilly
LLY
$776.08
(-2.40%)
$-19.04
AstraZeneca Plc
AZN
$69.85
(-0.31%)
$0.22
Johnson & Johnson
JNJ
$152.45
(0.29%)
$0.44
Mylan
MYL
Allergan
AGN
Bristol Myers Squibb
BMY
$46.34
(-0.67%)
$0.31
Teva Pharmaceutical Industries
TEVA
$16.75
(1.18%)
$0.20
Biogen
BIIB
$126.00
(-0.72%)
$0.92
Rigel Pharmaceuticals
RIGL
$19.54
(4.13%)
$0.78
Perrigo Plc
PRGO
$26.54
(-0.11%)
$0.03
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Hims & Hers Stock Investors Need to Know This Before Buying or Selling This Growth Stock
Hims & Hers Stock Financial Analysis Following Huge Stock Price Crash
Which Stock Will Dominate the Weight Management Market Through 2030?
3 No-Brainer Stocks to Buy for Under $100 Right Now
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.